Adagio Medical Holdings (ADGM)
NASDAQ:ADGM
Want to see ADGM full AI Analyst Report?
ADGM Stock Chart & Stats
$1.08
-$0.11(-9.46%)
At close: 4:00 PM EST
$1.08
-$0.11(-9.46%)
Day’s Range― - ―
52-Week Range$0.74 - $2.58
Previous Close$1.04
Volume669.05K
Average Volume (3M)152.12K
Market Cap
$21.66M
Enterprise Value$19.49M
Total Cash (Recent Filing)$17.11M
Total Debt (Recent Filing)$21.76M
Price to Earnings (P/E)―
Beta-0.25
Next Earnings
May 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.58
Shares Outstanding22,210,459
10 Day Avg. Volume84,483
30 Day Avg. Volume152,119
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)1.39
Price to Sales (P/S)0.00
P/FCF Ratio-0.89
Enterprise Value/Market Cap0.90
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-21.17
Enterprise Value/Ebitda-0.80
Forecast
1Y Price Target
$3.50Price Target Upside224.07% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.95
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Pivotal FULCRUM‑VT ResultsRobust six‑month pivotal data that met safety and effectiveness endpoints materially de‑risks the clinical profile of vCLAS. Durable clinical evidence supports physician adoption, strengthens PMA case, and underpins long‑term market credibility versus incumbent VT ablation options.
FDA IDE Expansion For Next‑gen VCLASAn IDE expansion is a structural regulatory win that enables prospective study of the next‑gen device. It accelerates pivotal evidence generation for label extension and PMA strategy, reducing regulatory uncertainty and supporting a sustained development-to-commercial pathway.
Platform Scalability And Efficiency GainsDesign goals to shorten procedures and improve manufacturability imply better workflow and unit economics if commercialized. Durable improvements in efficiency and scaleability can lower adoption barriers, reduce per‑case costs, and increase hospital willingness to integrate the technology.
Bears Say
No Meaningful RevenueA lack of commercial revenue through 2025 indicates the company is pre‑commercial and cannot self‑fund operations. This structural absence of sales prolongs dependence on external capital, delays path to profitability, and increases execution risk around market launch and scaling.
Persistent Negative Cash FlowConsistent negative operating and free cash flow demonstrate ongoing cash burn and reliance on financings. Persistent outflows constrain R&D and commercial investments, raise dilution risk, and limit runway flexibility absent material financing or partnerships.
Elevated Leverage And Balance‑sheet StressDebt exceeding equity and historical negative equity reflect material balance‑sheet weakness. Elevated leverage increases financing costs, restricts strategic options, and heightens vulnerability to setbacks, reducing ability to invest in commercialization or endure longer development timelines.
Adagio Medical Holdings News
ADGM FAQ
What was Adagio Medical Holdings’s price range in the past 12 months?
Adagio Medical Holdings lowest stock price was $0.74 and its highest was $2.58 in the past 12 months.
What is Adagio Medical Holdings’s market cap?
Adagio Medical Holdings’s market cap is $21.66M.
When is Adagio Medical Holdings’s upcoming earnings report date?
Adagio Medical Holdings’s upcoming earnings report date is May 14, 2026 which is in 4 days.
How were Adagio Medical Holdings’s earnings last quarter?
Adagio Medical Holdings released its earnings results on Apr 06, 2026. The company reported -$0.21 earnings per share for the quarter, beating the consensus estimate of -$0.31 by $0.1.
Is Adagio Medical Holdings overvalued?
According to Wall Street analysts Adagio Medical Holdings’s price is currently Undervalued.
Does Adagio Medical Holdings pay dividends?
Adagio Medical Holdings does not currently pay dividends.
What is Adagio Medical Holdings’s EPS estimate?
Adagio Medical Holdings’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Adagio Medical Holdings have?
Adagio Medical Holdings has 22,210,459 shares outstanding.
What happened to Adagio Medical Holdings’s price movement after its last earnings report?
Adagio Medical Holdings reported an EPS of -$0.21 in its last earnings report, beating expectations of -$0.31. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Adagio Medical Holdings?
Currently, no hedge funds are holding shares in ADGM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Adagio Medical Holdings
Adagio Medical Holdings, Inc., a developmental stage medical device company, focuses on the development and commercialization of ablation technologies for the treatment of cardiac arrhythmias. It offers treatment for cardiac arrhythmias, including atrial fibrillation, atrial flutter, and ventricular tachycardia. The company's product portfolio includes iCLAS atrial ultra-low temperature cryoablation (ULTC) catheter and accessories; vCLAS ventricular ULTC catheter; and Cryopulse atrial pulsed-field cryoablation catheter and accessories. Adagio Medical Holdings, Inc. was founded in 2011 and is headquartered in Laguna Hills, California.
ADGM Stock 12 Month Forecast
Average Price Target
$3.50
▲(224.07% Upside)
Technical Analysis
Co-Diagnostics
―
PAVmed
―
Vivos Therapeutics
―
Inspira Technologies Oxy BHN
―
Envoy Medical
―
Ownership Overview
45.47% Insiders
0.41% Mutual Funds
0.12% Other Institutional Investors
53.82% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---